THNR ETF
Amplify Weight Loss Drug & Treatment ETF
THNR ETF Overview
THNR ETF (Amplify Weight Loss Drug & Treatment ETF) is managed by Amplify ETFs with $5.5M in net assets. THNR expense ratio is 0.59%, holding 45 positions across sectors including Health Care, Financials. Inception date: 2024-05-21.
THNR performance shows a YTD return of -1.10%. The 1-year return is 8.83%. THNR dividend yield stands at 1.64%, paid annually.
THNR top holdings include Eli Lilly & Co. (10.2%), Novo-Nordisk A/S-Spons Adr (8.4%), CSPC Pharmaceutical Group Limited Shs (5.9%), Amgen Inc. (5.7%), Pfizer Inc (5.4%). Go to all THNR holdings, THNR sectors, or THNR dividends.
THNR can be compared against other funds. Use THNR overlap to find shared positions, or THNR vs another fund for a side-by-side view. THNR alternatives are available via the screener, along with tax-loss harvesting opportunities.